Migraine as a Public Health Challenge: Contemporary Perspectives on Pathophysiology, Diagnosis and Treatment
DOI:
https://doi.org/10.12775/JEHS.2026.94.72978Keywords
Migraine Disorders, Calcitonin Gene-Related Peptide, Headache, Public Health, Diagnosis, TherapeuticsAbstract
Introduction and purpose: Migraine is a common and disabling neurological disorder with substantial public health relevance. It affects education, work productivity, social functioning, and quality of life, particularly among adolescents and adults of working age. The aim of this review is to summarize contemporary perspectives on migraine epidemiology, risk factors, pathophysiology, clinical classification, comorbidities, and current treatment strategies.
Brief description of the state of knowledge: Current evidence presents migraine as a complex disorder of sensory processing and neural network dysfunction rather than a purely vascular disease. Important mechanisms include activation of the trigeminovascular system, altered cortical and brainstem excitability, calcitonin gene-related peptide signaling, cortical spreading depression in migraine with aura, and peripheral and central sensitization. Diagnosis remains primarily clinical and should follow the International Classification of Headache Disorders criteria. Treatment includes acute pharmacotherapy, preventive drugs, anti-CGRP therapies, neuromodulation, education, lifestyle modification, regular physical activity, sleep regulation, and management of comorbid psychiatric, vestibular, sleep-related, and cardiovascular conditions.
Summary: Migraine should be understood both as a neurological disease and as a public health challenge. Effective care requires individualized, multidisciplinary management that combines evidence-based pharmacological treatment with non-pharmacological support and long-term patient education.
References
1. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. https://doi.org/10.1186/s10194-020-01208-0
2. Husøy AK, Xu YY, Steinmetz JD, et al. Global, regional, and national burden of headache disorders, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Neurol. 2025;24(12):1005-1015. https://doi.org/10.1016/S1474-4422(25)00402-8
3. World Health Organization. Migraine and other headache disorders. WHO website. Accessed June 5, 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/headache-disorders
4. Ahmad SR, Rosendale N. Sex and gender considerations in episodic migraine. Curr Pain Headache Rep. 2022;26(7):505-516. https://doi.org/10.1007/s11916-022-01052-8
5. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553-622. https://doi.org/10.1152/physrev.00034.2015
6. Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619-6629. https://doi.org/10.1523/JNEUROSCI.0373-15.2015
7. Khan J, Asoom LIA, Sunni AA, et al. Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomed Pharmacother. 2021;139:111557. https://doi.org/10.1016/j.biopha.2021.111557
8. Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia. 2019;39(3):445-458. https://doi.org/10.1177/0333102418821662
9. Zobdeh F, ben Kraiem A, Attwood MM, et al. Pharmacological treatment of migraine: drug classes, mechanisms of action, clinical trials and new treatments. Br J Pharmacol. 2021;178(23):4588-4607. https://doi.org/10.1111/bph.15657
10. Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501-514. https://doi.org/10.1038/s41582-021-00509-5
11. Aguilar-Shea AL, Membrilla MD, Diaz-de-Teran J. Migraine review for general practice. Aten Primaria. 2022;54(2):102208. https://doi.org/10.1016/j.aprim.2021.102208
12. Amiri P, Kazeminasab S, Nejadghaderi SA, et al. Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol. 2022;12:800605. https://doi.org/10.3389/fneur.2021.800605
13. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia. 1992;12(4):221-228. https://doi.org/10.1046/j.1468-2982.1992.1204221.x
14. Kotowicz Z, Pabiś J, Podgórski P, Górecka S, Olszański M, Bogusz A, et al. Strategies for Treating Acute Migraines and Identifying Triggers. Literature review. J Educ Health Sport. 2024;69:49179. https://doi.org/10.12775/JEHS.2024.69.49179
15. Tanaka M, Tuka B, Vécsei L. Navigating the neurobiology of migraine: from pathways to potential therapies. Cells. 2024;13(13):1098. https://doi.org/10.3390/cells13131098
16. Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the trigeminal system in migraine. Headache. 2019;59(5):659-681. https://doi.org/10.1111/head.13529
17. Wrobel Goldberg S, Silberstein SD. Targeting CGRP: a new era for migraine treatment. CNS Drugs. 2015;29(6):443-452. https://doi.org/10.1007/s40263-015-0253-z
18. Noseda R, Jakubowski M, Kainz V, Borsook D, Burstein R. Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms. J Neurosci. 2011;31(40):14204-14217. https://doi.org/10.1523/JNEUROSCI.3285-11.2011
19. Riederer F, Beiersdorf J, Scutelnic A, Schankin CJ. Migraine aura-catch me if you can with EEG and MRI-a narrative review. Diagnostics (Basel). 2023;13(17):2844. https://doi.org/10.3390/diagnostics13172844
20. Lucas C. Migraine with aura. Rev Neurol (Paris). 2021;177(7):779-784. https://doi.org/10.1016/j.neurol.2021.07.010
21. Grodzka O, Dzagoevi K, Rees T, et al. Migraine with and without aura-two distinct entities? A narrative review. J Headache Pain. 2025;26(1):77. https://doi.org/10.1186/s10194-025-01998-1
22. Schoonman GG, Evers DJ, Terwindt GM, van Dijk JG, Ferrari MD. The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia. 2006;26(10):1209-1213. https://doi.org/10.1111/j.1468-2982.2006.01195.x
23. Lipton RB, Lanteri-Minet M, Leroux E, et al. Pre- and post-headache phases of migraine: multi-country results from the CaMEO-International Study. J Headache Pain. 2023;24(1):151. https://doi.org/10.1186/s10194-023-01683-1
24. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. https://doi.org/10.1177/0333102417738202
25. May A. Hints on diagnosing and treating headache. Dtsch Arztebl Int. 2018;115(17):299-308. https://doi.org/10.3238/arztebl.2018.0299
26. Cieszkowska J, Otręba K, Czupryńska K, Daniel P, Leśkiewicz M, Składanek JA. Diagnosis and treatment of migraine: an analysis of the latest diagnostic and therapeutic guidelines. J Educ Health Sport. 2024;74:51722. https://doi.org/10.12775/JEHS.2024.74.51722
27. Benjamin T, Gillard D, Abouzari M, Djalilian HR, Sharon JD. Vestibular and auditory manifestations of migraine. Curr Opin Neurol. 2022;35(1):84-89. https://doi.org/10.1097/WCO.0000000000001024
28. Skrzypek J, Niewiadomska J, Bondos B, Stępień A, Paluch A, Niekra A, et al. Episodic and chronic migraine - treatment and risk factors - A literature review. J Educ Health Sport. 2024;75:56459. https://doi.org/10.12775/JEHS.2024.75.56459
29. VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA. 2021;325(23):2357-2369. https://doi.org/10.1001/jama.2021.7939
30. Digre KB. What’s new in the treatment of migraine? J Neuroophthalmol. 2019;39(3):352-359. https://doi.org/10.1097/WNO.0000000000000837
31. Słychan K, Frańczuk A, Makłowicz A, Szpulak A, Kopczyńska E, Głoskowska J, et al. Advances in migraine treatment - a review. Qual Sport. 2024;21:54055. https://doi.org/10.12775/QS.2024.21.54055
32. Nicol KS, Burkett JG. Review: an update on CGRP monoclonal antibodies for the preventive treatment of episodic migraine. Curr Pain Headache Rep. 2025;29(1):55. https://doi.org/10.1007/s11916-025-01365-4
33. Dai O, Chen S, Zhang TH, et al. Discovery, structural characterization, chemical synthesis, anti-migraine effect, and pharmacological mechanism of ligualkaloid B: an alkaloid from Ligusticum chuanxiong. Bioorg Chem. 2026;173:109699. https://doi.org/10.1016/j.bioorg.2026.109699
34. Waliszewska-Prosół M, Straburzyński M, Kopka M, Nowaczewska M. Migraine – contemporary treatment methods, future therapies. Polish Neurological Review. 2021;17(1):19-35. https://doi.org/10.5603/PPN.2021.0003
35. Diener HC, Goadsby PJ, Ashina M, et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia. 2019;39(12):1475-1487. https://doi.org/10.1177/0333102419876920
36. Yuan H, Orr SL, Al-Karagholi MAM, et al. International Headache Society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine. Cephalalgia. 2025;45(10):3331024251388377. https://doi.org/10.1177/03331024251388377
37. Hong P, Liu Y, Wan Y, Xiong H, Xu Y. Transcranial direct current stimulation for migraine: a systematic review and meta-analysis of randomized controlled trials. CNS Neurosci Ther. 2022;28(7):992-998. https://doi.org/10.1111/cns.13843
38. Al-Kaisy A, Palmisani S, Carganillo R, et al. Safety and efficacy of 10 kHz spinal cord stimulation for the treatment of refractory chronic migraine: a prospective long-term open-label study. Neuromodulation. 2022;25(1):103-113. https://doi.org/10.1111/ner.13465
39. Woldeamanuel YW, Oliveira ABD. What is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta-analysis of clinical trials. J Headache Pain. 2022;23(1):134. https://doi.org/10.1186/s10194-022-01503-y
40. Belcarz W, Kalinowska K, Paprocka A, Świrk U, Fijałek P, Karczmarz J, et al. The Relationship Between Physical Activity and Migraines: Research on Prevention and Supportive Treatment. Qual Sport. 2025;38:58213. https://doi.org/10.12775/QS.2025.38.58213
41. Carvalho GF, Schwarz A, Szikszay TM, Adamczyk WM, Bevilaqua-Grossi D, Luedtke K. Physical therapy and migraine: musculoskeletal and balance dysfunctions and their relevance for clinical practice. Braz J Phys Ther. 2020;24(4):306-317. https://doi.org/10.1016/j.bjpt.2019.11.001
42. Chaibi A, Tuchin PJ, Russell MB. Manual therapies for migraine: a systematic review. J Headache Pain. 2011;12(2):127-133. https://doi.org/10.1007/s10194-011-0296-6
43. Nguyen KV, Schytz HW. The evidence for diet as a treatment in migraine-a review. Nutrients. 2024;16(19):3415. https://doi.org/10.3390/nu16193415
44. Singh V, Kumar A, Ray S, Chakravarty K, Lall N, Joshi D. Non-pharmacological approaches for migraine management: a mini-review. Front Pain Res (Lausanne). 2026;7:1760756. https://doi.org/10.3389/fpain.2026.1760756
45. Mendak M, Hanslik A, Białek A, Walczak A, Olszanecka M, Olszanecki T, et al. The Impact of Migraine and Therapeutic Intervention Methods on Subjective Quality of Life Assessment. Information overview. Qual Sport. 2025;38:58161. https://doi.org/10.12775/QS.2025.38.58161
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Pola Kobryń, Igor Nowiński, Dawid Ocicki, Michał Bojarski, Michał Kwiatkowski, Michał Musielak, Iga Kobryń, Aleksandra Zybert, Aleksandra Borowska, Jakub Grabowski

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 33
Number of citations: 0